• Intellia Therapeutics will present Phase 1 nex-z data at American Heart Association Scientific Sessions in Chicago, Nov. 6-9, 2026.
• The Nov. 9 presentation will highlight cardiac outcomes following a single dose in hereditary transthyretin amyloidosis patients with polyneuropathy and cardiac involvement.
• A Nov. 18 presentation will cover up to four years of follow-up in patients with hereditary transthyretin amyloidosis with polyneuropathy.
• That presentation is scheduled for the International Society of Amyloidosis symposium, held Nov. 15-18, 2026, in Montevideo, Uruguay.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030800PRIMZONEFULLFEED9868330) on November 03, 2026, and is solely responsible for the information contained therein.